GALT

NASDAQStock

Galectin Therapeutics Inc.

$3.06-0.10 (-3.32%)

52-Week Range

$1.22

$6.51

Key Stats

Market Cap

—

P/E Ratio

—

Dividend Yield

—

Beta

1.01

Volume

229.0K

Avg Volume

414.5K

Performance

+12.46%

-51.46%

-29.78%

YTD

-21.98%

+88.10%

+66.32%

+26.40%

Price Chart

ETF Exposure

GALT is held by 10 ETFs

ETF	Fund Name	Weight	Shares	Market Value	Fund AUM	Expense Ratio
MEDX	Horizon Kinetics Medical ETF	0.85%	51,484	$163K	$19.6M	0.85%
QQQS	Invesco NASDAQ Future Gen 200 ETF	0.25%	11,563	$35K	$13.4M	0.20%
IWC	iShares Micro-Cap ETF	0.03%	121,502	$366K	$1.27B	0.60%
VXF	Vanguard Extended Market ETF	0.00%	563,630	$1.6M	$84.10B	0.05%
VCNS.TO	Vanguard Conservative ETF Portfolio	0.00%	66	$254	$820.6M	0.25%
VEQT.TO	Vanguard All-Equity ETF Portfolio	0.00%	2,373	$9K	$12.17B	0.24%
VRIF.TO	Vanguard Retirement Income ETF Portfolio	0.00%	11	$44	$337.7M	0.32%
VTI	Vanguard Total Stock Market ETF	0.00%	1,351,443	$3.8M	$2.10T	0.03%
VUN.TO	Vanguard U.S. Total Market Index ETF	0.00%	7,108	$27K	$15.33B	0.17%
VUS.TO	Vanguard U.S. Total Market Index ETF (CAD-hedged)	0.00%	612	$2K	$1.29B	0.17%

About GALT ETF Exposure

Galectin Therapeutics Inc. (GALT) is held by 10 exchange-traded funds, making it one of the stocks with significant ETF exposure. The stock currently trades at $3.06. Investors can gain exposure to GALT through a variety of ETFs with different expense ratios, investment strategies, and portfolio weightings. The table above shows all ETFs that currently hold GALT, sorted by portfolio weight.